Deerfield Management Company, L.P. (Series C) Nuvation Bio Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 45,448 shares of NUVB stock, worth $106,348. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,448
Previous 20,166
125.37%
Holding current value
$106,348
Previous $53,000
49.06%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding NUVB
# of Institutions
167Shares Held
156MCall Options Held
4.6KPut Options Held
154K-
Decheng Capital LLC Menlo Park, CA26MShares$60.7 Million12.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.4MShares$36 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$30.6 Million47.43% of portfolio
-
Laurion Capital Management LP New York, NY9.87MShares$23.1 Million0.45% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $508M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...